Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI

Exclusion Criteria

• •(1) Cardiogenic shock, Killip III-IV grade, papillary muscle rupture, interventricular septal perforation, ventricular ventricular fibrillation and electrical cardioversion, and III degree AVB implantation of temporary pacemaker before PCI;
• •(2) LVEF ≤ 30%;
• •(3) Previous history of PCI and CABG history;
• •(4) acute and chronic infectious diseases (severe pneumonia, etc.);
• •(5) Recent history of hemorrhagic stroke (within six months);
• •(6) Combining liver and kidney dysfunction caused by various reasons;
• •(7) History of valvular heart disease;
• •(8) Congenital heart disease and pulmonary hypertension;
• •(9) History of various types of cardiomyopathy;
• •(10) bleeding and other thrombotic diseases;
• •(11) severe anemia, thrombocytopenia and other blood system diseases;
• •(12) Patients with malignant tumors, autoimmune diseases, and various causes of glucocorticoids and immunosuppressive agents;
• •(13) Patients with a history of drug allergy, allergic diseases or allergies, or patients who are allergic to any of the ingredients in this product;
• •(14) Patients with severe mental or neurological diseases;
• •(15) pregnant women, lactating women, and subjects with a pregnancy plan during the trial;
• •(16) According to the investigator's judgment, the subject is unable to complete the study or may not be able to comply (for administrative reasons or other reasons) the subjects required for this study.
• •(17) Patients who have participated in other clinical trials in the past 3 months.Researchers believe that it is not appropriate to participate in this clinical trial.